Background Fibrinogen-depleting agents are promising in the treatment of cerebral ischemic disease. They were studied by many trials, and the outcomes were different because of different regimens and different doses. In this study, we assessed the efficacy and safety of defibrase on acute cerebral infarction in China. Methods A search using Chinese hospital knowledge database (CHKD) and MEDLINE database for randomized controlled trials was carried out. A CHKD (1994( June 2005 search was performed with the keyword "defibrase", then a second search for the keyword "acute cerebral infarction"; a MEDLINE search (1950( June 2005 was performed with the following keywords: [(cerebral ischemia), OR (acute cerebral infarction), OR (stroke)], AND [defibrase]. Meta-analysis was performed with RevMan software 4.2. Results Included were 14 studies comparing the efficiency and safety of defibrase with other drugs in the treatment of acute cerebral infarction. Patients' records were pooled (total 646 patients; defibrase, n=328, no defibrase n=318). Neurological deficit score (NDS) before treatment showed weighted mean differences (WMD)=0.95, 95% confidence interval (CI)= (-0.60, 2.50), P=0.23; NDS after treatment showed WMD=-2.20, 95% CI= (-4.21, -0.18), P=0.03; Barthel index at 3 months showed WMD=4.45, 95% CI= (-0.13, 9.03), P=0.06; the plasma fibrinogen level before treatment showed WMD=0.02, 95% CI= (-0.16, 0.19), P=0.86; plasma fibrinogen level after treatment showed WMD=-1.51, 95% CI= (-1.88, -1.15), P<0.00 001. Conclusions With the given dose and regimen of defibrase in China, defibrase may play a role of anticoagulation. It might inhibit the progression of stroke and prevent the recurrence of stroke.
clinical trials should be prospective, controlled randomized trials. 3 . Each trial should focus on the defibrogenic treatment of acute cerebral infarction (within 24 hours of symptom onset). In the trial, the treatment group used defibrase and the control group used placebo. Both groups used calcium channel antagonists and dilatancy agents except other kinds of fibrinogen-depleting agents, anticoagulants, thrombolysis agents or platelet aggregation inhibitors. 4 . The therapeutic effect should be demonstrated by measurement of neurological deficit score (NDS), Barthel index, and numeration data such as plasma fibrinogen level. Case inclusion criteria: (1) Patients must be within 24 hours of stroke onset and intracranial hemorrhage should be excluded by cranial CT scan; (2) Patients should not be in coma; (3) Myodynamia should vary from grade 0 to grade IV; (4) The age of patients should range from 35 to 75 years; (5) Patients should agree on the therapeutic design. Case exclusion criteria: (1) Patients suffered from intracranial hemorrhage before or had a history of stroke within 6 months; (2) Patients underwent epileptic seizure at stroke onset; (3) Blood glucose level was < 2 mmol/L or > 10 mmol/L. 5. Acute cerebral infarction was diagnosed according to the diagnostic criteria set up at the Fourth Cerebravascular Diseases Conference in 1995. 3 Literature exclusion criteria: (1) statistical data being not consistent with the selection criteria; (2) repeated articles and literatures; and (3) use of other fibrinogen-depleting agents in the control group.
Regimen design
A meta-analysis was made of individual patient data from randomized controlled double-blind trials and controlled clinical studies of defibrase in patients with acute cerebral infarction. The treatment group utilized defibrase 10-15 U adding into 250 saline, dripping 2 hours via the vein, then 5 U dripping once every other day for 2 or 4 times. The control group used placebo but the regimen of placebo was similar to that of defibrase.
Search source
A search for randomized controlled trials was based on Chinese hospital knowledge database (CHKD, 1994-June 2005) and MEDLINE database (1950 ( -June 2005 .
Search strategy
A comprehensive literature search was performed to identify all eligible randomized controlled trials of defibrase in the treatment of acute cerebral infarction. CHKD (1994 to June 2005 inclusive) was searched with the keyword "defibrase", followed by a second key term "acute cerebral infarction"; MEDLINE (1950 to June 2005 inclusive) was searched with the keywords cerebral ischemia, acute cerebral infarction, stroke, and defibrase.
Data management
The data were initially analyzed as in the trial publication to ensure consistency. Trialists were contacted to resolve any difference or ambiguity. The data were re-coded and merged into a single data set for analysis. The primary outcome measurement included NDS before treatment, NDS at 2 weeks after treatment, Barthel index at 3 months after treatment, plasma fibrinogen level before and after treatment. The measuring scales consisted of standard scale of clinical neurological deficit formulated at the Fourth Cerebrovascular Diseases Conference in China and ability of daily living (ADL) scale (Barthel index).
According to the inclusion criteria, two reviewers independently selected trials, assessed trial quality, and extracted data from each trial. Finally, they came to an agreement on final selection of trials. According to the literature of Lichtenstein, the trials with repeated case report, poor quality, and little information should be excluded.
Statistical analysis
The heterogeneity test (Q-test) was conducted for the effect measurement of selected articles. If there was no statistically significant difference among the results, the fixed effect model was applied; if there was statistical difference among the results, the random effect model was applied. The whole data were analyzed by RevMan software 4.2.
RESULTS

Trial searches and study characteristics
Bibliographic search yielded 128 articles. Of which, 114 were excluded. Among the 114 articles, 86 were excluded for the absence of statistical data (NDS, Barthel index, and plasma fibrinogen level), 12 for 
Heterogeneity
The result of the heterogeneity test in NDS (before treatment) showed P=0.65, indicating no evidence of heterogeneity in 14 studies, hence fixed effect model was used. NDS (after treatment) was P=0.04, and Barthel index was P=0.008. The value for plasma fibrinogen level before and after treatment was P=0.03 and P<0.000 01, respectively. They all showed significant evidence of heterogeneity in 14 studies, thus random effect model was applied to them.
Outcomes
Patients' records were pooled (total 646 patients; 328 in defibrase group, 318 in control group). NDS before treatment showed WMD=0.95, 95% CI= (-0.60, 2.50), P=0.23; NDS after treatment showed WMD= -2.20, 95% CI=(-4.21, -0.18), P=0.03; Barthel index showed WMD=4.45, 95% CI=(-0.13, 9.03), P=0.06; plasma fibrinogen level before treatment showed WMD=0.02, 95% CI=(-0.16, 0.19), P=0.86; the plasma fibrinogen level after treatment showed WMD=-1.51, 95% CI=(-1.88, -1.15), P<0.000 01. These results showed that the effect of defibrase in neurological deficit score (NDS) was higher than that of other drugs at 2 weeks after treatment of acute cerebral infarction, and that plasma fibrinogen level decreased more significantly than that after use of other drugs. Twelve weeks after treatment, however, there was no significant difference in Barthel index.
DISCUSSION
Ancrod as a kind of fibrinogen-depleting agents frequently used in North America and Europe was used for the treatment of acute stroke as early as in 1983 and 1988. In a recent Stroke Treatment with Ancrod Trial (STAT, 1993), patients were randomized to receive continuous 72-hour intravenous infusion within 3 hours after stroke. Ancrod was administered at initial infusion rates of 0.167, 0.125, and 0.082 IU/kg per hour based on pretreatment fibrinogen levels of more than 4.50, 3.50 to 4.49 and 1.00 to 3.49 g/L, respectively. 18 The ancrod regimen was designed to decrease plasma fibrinogen levels to 0.40-0.69 g/L. The primary efficacy end point was a favorable functional status defined as survival to day 90 with a Barthel Index of 95 or more. Favorable functional status was achieved in 42.2% of the ancrod group compared to 34.4% of the placebo group (P=0.04). The mortality rate was almost similar, whereas the incidence of symptomatic hemorrhage was higher in patients who received ancrod (5.2% vs 2.0%, P=0.06). In contrast to STAT, the European Stroke Treatment with Ancrod Trial (ESTAT, 1998) has a similar design with a 6-hour window for randomization from stroke symptom onset. 19 The trial was terminated for the increased mortality in 90 days and significantly increased hemorrhage as compared with the control group. 20
In the cases selected in our meta-analysis, the time window was 24 hours, and defibrase was given as an initial dose of 10-15 U, then 5 U once every other day for 2 or 4 times. The result demonstrated more favorable recovery of neurological function at 2 weeks after treatment and more decreased levels of plasma fibrinogen than those in the control group. But no prominent activities of daily life were observed as compared with the control group at 3 months after treatment.
We postulate that different results among China, North America and Europe were due to different time windows for treatment, different target levels of plasma fibrinogen after treatment, and different regimens of fibrinogen-depleting agents.
The time window
In STAT and ESTAT, the time window was 3 and 6 hours respectively; it was similar to the time window for thrombolysis. We speculate that it plays an important role in thrombolysis. The effect of the treatment is favorable within 3 hours of stroke. However, the ESTAT was terminated owing to increased intracranial hemorrhage after the treatment within 6 hours of stroke. In the two trials of CGRD in China, the time window was 24 and 12 hours, respectively. The first trial had no significant outcome at 2 weeks and 3 months after the treatment of the defibrase group, but the incidence of one-year recurrence decreased. In the second trial, the time window was shortened to 12 hours. Obvious improvement was seen in neurological functional deficits at 2 weeks and in ability to sustain daily life at 3 months compared with the control group (P=0.001). In the patient who started the treatment in and later than 6 hours separately, those receiving earlier treatment (in 6 hours) had a favorable functional status at 3 months or a lower dependent functional status, whereas no significant difference was observed in the defibrase group and the placebo group when the treatment started in the time window of 6 -12 hours (P=0.086). 21 These results demonstrated that the treatment within 6 hours of stroke onset was definitely effective. It is assumed that when the dose and regimen of defibrase is set for a time window of 12-24 hours, anticoagulation might inhibit the progression of stroke and prevent the recurrence of stroke.
The target level of plasma fibrinogen after treatment
In STAT and ESTAT, ancrod was given continuously for 72 hours, and the plasma fibrinogen was maintained at the target levels of 0.4-0.7 g/L, which ensure the efficacy and safety of defibrase treatment. The first trial in China did not identify the target level, and the plasma fibrinogen levels in 60% of patients after the treatment were higher than 2 g/L, resulting in the failure of defibrase treatment. In the second trial, the initial dose of defibrase was increased to 15 U, the duration of treatment was also increased (5 U once every other day for 4 times). The trial also did not identify a comparatively reasonable target level, but statistically the plasma fibrinogen level in 60% of patients after the treatment was lower than 1.3 g/L, indicating more favourable effect in the treatment group than in the control group, apart from increased incidence of hemorrhage. In other clinical trials the therapeutic efficacy of defibrase was assumed to be related to the plasma fibrinogen level after the treatment. 19 Therefore, further investigation is required to explore an efficient and safe target level of plasma fibrinogen.
The regimen of fibrinogen-depleting agents
In STAT, the initial dose was based on pretreatment fibrinogen levels, and ancrod was infused intravenously for 72 hours to decrease the level of plasma fibrinogen to the target level as soon as possible. But the dose in the trials conducted by CGRD in China was fixed for 10, 5, 5 U or 15, 5, 5, 5, 5 U, and the time of treatment was also fixed (given every other day). The disadvantage of this regimen was due to the underevaluation of the plasma fibrinogen levels before and after the treatment, and the same dose for all patients. Moreover, the different sensibility of patients to defibrase led to difficulty in decreasing plasma fibrinogen level to target level in some patients, resulting in plasma fibrinogen level higher than target level after treatment or increased incidence of hemorrhage, ie the plasma fibrinogen level lower than target level after treatment.
The second trial of CGRD in China showed favourable results, but in the defibrase group there was no difference in functional outcome between patients with high (>1.3 g/L) and low (<1.3 g/L) plasma fibrinogen levels at 3 months after the treatment. However, the incidences of symptomatic intracranial hemorrhage and extracranial hemorrhage were significantly higher in patients with plasma fibrinogen level <1.3 g/L than in those with plasma fibrinogen level >1.3 g/L. In STAT, Barthel index at 3 months after the treatment was 20, which was higher in patients with plasma fibrinogen level <1.3 g/L than in those with plasma fibrinogen level >1.3 g/L. The contradictory results were possibly due to the time window as well as the single dose and fixed regimen in China. Therefore, comparison of STAT and ESTAT showed blindness of the administration design of defibrase in China (Whatever the plasma fibrinogen level was, the dose of defibrase was the same as 10, 5, 5 U, or 15, 5, 5, 5, 5 U administered every other day). Thus the therapeutic efficacy at present could not represent the best regimen and efficacy of defibrase.
In this study, we had the following limitations: 1. In most articles, randomization was not described in detail that we could not know whether the trial was performed correctly and whether allocation concealment was made adequately, which otherwise might magnify the therapeutic efficacy. 2. In the selected trials, two kinds of interventional method (10, 5, 5 U, and 15, 5, 5, 5, 5 U) might result in statistical heterogeneity for each trial. 3. As the trials were already published in journals, excluding such grey literature as special subject reports, enunciable data, government reports, and other traditional or nontraditional sources of literatures, we failed to make general assessment.
In conclusion, high plasma fibrinogen level is recognized as an independent dangerous factor for the occurrence of stroke. Fibrinogen-depleting agents are thought to decrease plasma fibrinogen level and are promising in the treatment and prevention of acute stroke. But stratified analysis is necessary of the plasma fibrinogen level and the severity of the disease in addition to long-term clinical study of fibrinogen-depleting agents. In this way the precaution and therapeutic efficacy of defibrase could be evaluated objectively. Currently, hundreds of millions of people suffer from chronic respiratory diseases, including 300 million people with asthma, 80 million people with moderate to severe chronic obstructive pulmonary disease (COPD) and millions of others with mild COPD, allergic rhinitis, and other chronic respiratory diseases, which are often undiagnosed. WHO estimates that some 4 million people died of chronic respiratory diseases (CRD) in 2005 and that total deaths will increase by 30% in the next 10 years, if action is not taken now. "The goal of GARD," says Professor Jean Bousquet, GARD chairman, "is to reduce the global burden of chronic respiratory diseases. As the prevalence and global burden of chronic respiratory diseases are expected to increase considerably in the near future, it is clear that immediate action is greatly needed and the cost for inaction is unacceptable."
The key objectives for GARD involve a comprehensive approach to fight chronic respiratory diseases and in many cases will build on already existing initiatives. In China, an estimated 17% of all deaths are due to chronic respiratory diseases. "Rapid urbanization in China has contributed to the sharp rise in chronic disease risk factors such as tobacco use, physical inactivity, and unhealthy diet. By creating a supportive environment where healthy choices are easy and accessible, healthy life years will be added for individuals and the society at large," says Dr Henk Bekedam, WHO Representative to China.
WHO advocates an integrated approach to prevention and care for all leading chronic diseases. Integrated approaches that combine chronic respiratory diseases prevention and management with a similar approach for heart disease, stroke, diabetes and other chronic diseases are necessary because the diseases share common risk factors and require similar responses from the health system. The integrated approach is not only best for prevention and management, it is also cost-effective. This approach is outlined in the recent released report, Preventing chronic diseases a vital investment, which also called for a Global Goal to reduce death rates from chronic respiratory diseases and other chronic diseases including heart disease, stroke, cancer and diabetes by an additional 2% per year over and above existing trends during the next 10 years, to 2015.
(Source: WHO)
